What is the price target for ELVN stock?
16 analysts have analysed ELVN and the average price target is 41.59 USD. This implies a price increase of 35% is expected in the next year compared to the current price of 30.81.
ENLIVEN THERAPEUTICS INC (ELVN) Forecast, Price Target & Analyst Ratings
NASDAQ:ELVN • US29337E1029
Current stock price
30.81 USD
+1.78 (+6.13%)
At close:
30.9 USD
+0.09 (+0.29%)
Pre-Market:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ENLIVEN THERAPEUTICS INC (ELVN).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.46
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$41.59
Upside
+ 35.00%
From current price of $30.81 to mean target of $41.59, Based on 16 analyst forecasts
Low
$33.33
Median
$39.78
High
$54.60
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
16 Wall Street analysts provided a forecast for the next 12 months for ELVN. The average price target is 41.59 USD. This implies a price increase of 35% is expected in the next year compared to the current price of 30.81.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.00%
ELVN was analyzed by 16 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about ELVN.
In the previous month the buy percentage consensus was at a similar level.
ELVN was analyzed by 16 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-07-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-16 | Baird | Maintains | Outperform -> Outperform |
| 2025-06-16 | Goldman Sachs | Initiate | Buy |
| 2025-05-16 | Jones Trading | Maintains | Buy -> Buy |
| 2025-05-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-12-13 | BTIG | Initiate | Buy |
| 2024-11-15 | Baird | Maintains | Outperform -> Outperform |
| 2024-10-31 | Jones Trading | Initiate | Buy |
| 2024-10-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-09 | HC Wainwright & Co. | Initiate | Buy |
| 2024-06-11 | Baird | Initiate | Outperform |
| 2024-04-09 | Mizuho | Initiate | Buy |
| 2023-03-29 | Jefferies | Initiate | Buy |
| 2023-03-03 | TD Cowen | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 12, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.46
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 18.79%
- Number of Analysts
- 9
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-8.62%
EPS (3 Months)
-8.62%
Next Earnings Summary
ELVN is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -0.46 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 625,468.63% | N/A 268.51% | N/A 129.24% | N/A 53.61% | N/A 33.14% | ||||||||||
| EBITDA YoY % growth | N/A | -10.68M | -24.09M -125.56% | -41.6M -72.69% | -51.34M -23.41% | -33.66M 34.44% | -83.232M -147.27% | -104.237M -25.24% | -119.395M -14.54% | N/A -35.41% | N/A -32.49% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -8.91M | -10.68M -19.87% | -24.12M -125.84% | -41.7M -72.89% | -51.44M -23.36% | -34.27M 33.38% | -83.529M -143.74% | -104.554M -25.17% | -119.658M -14.45% | N/A -25.35% | N/A -36.77% | N/A -25.22% | N/A 13.05% | N/A 63.35% | N/A 502.79% | N/A 106.20% | N/A 37.81% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -24.72 | -9.60 61.17% | N/A 84.72% | -2.19 -49.31% | -1.89 13.70% | -1.86 1.59% | N/A -7.69% | N/A -35.78% | N/A 15.99% | N/A 36.61% | N/A 129.58% | N/A 742.86% | N/A 107.06% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.46 18.79% | -0.46 5.66% | -0.51 -58.67% | -0.51 -6.57% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | -32.533M -2.89% | -37.223M -30.93% | -41.812M -68.06% | N/A |
| EBIT Q2Q % growth | -32.957M -3.99% | -32.63M -14.15% | -35.308M -40.69% | -35.743M -4.25% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-7.10%
EPS Next 5 Year
17.40%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
20.52%
Revenue Next 5 Year
734.04%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
ENLIVEN THERAPEUTICS INC / ELVN Forecast FAQ
When does ENLIVEN THERAPEUTICS INC (ELVN) report earnings?
ENLIVEN THERAPEUTICS INC (ELVN) will report earnings on 2026-05-12.
What are the consensus estimates for ENLIVEN THERAPEUTICS INC (ELVN) next earnings?
The consensus EPS estimate for the next earnings of ENLIVEN THERAPEUTICS INC (ELVN) is -0.46 USD and the consensus revenue estimate is 0 USD.
How many analysts cover ENLIVEN THERAPEUTICS INC (ELVN) stock?
The number of analysts covering ENLIVEN THERAPEUTICS INC (ELVN) is 16.